Anzeige
Mehr »
Login
Montag, 23.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Die erste börsennotierte Gesellschaft, die auf das gemeinsame Wachstum von Solana, XRP und Dogecoin setzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
357 Leser
Artikel bewerten:
(2)

Pace® Analytical: Pace Life Sciences Division Names Dean Bornilla as Head of Commercial

Finanznachrichten News

Bornilla brings over 25 years of commercial pharmaceutical experience to Pace®

MINNEAPOLIS, MN / ACCESSWIRE / July 23, 2024 / Pace®?Life Sciences, a full-service contract development and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, announced today that Dean Bornilla has been named Head of Commercial reporting to Dawn Von Rohr, President, Pace® Life Sciences.

Pace Life Sciences Logo

Pace Life Sciences Logo
Full color PNG logo

Pace® Life Sciences provides laboratory testing and professional services to pharmaceutical and biopharmaceutical manufacturers, ranging from early-stage drug research and development to commercialization, recently adding services and capacity through acquisitions. Drawing on more than 25 years of pharmaceutical expertise, Bornilla will lead commercial growth teams in partnering with new and existing clients and building upon the company's reputation for quality, agility, and accelerating the drug development process through direct collaboration with acclaimed scientists.

"Dean's commitment to excellence and innovation coupled with his proven track record and leadership experience will be valuable to Pace® and our clients," states Dawn Von Rohr, President, Pace® Life Sciences. "I'm confident that he will be successful in helping us to elevate our offerings in the pharmaceutical industry."

Prior to Pace®, Bornilla was Head of North America sales for Selvita where he built a US drug discovery and development commercial platform. He also served at Curia, formerly AMRI, where his strong leadership skills and commercial acumen expanded the company's drug discovery & development, API manufacturing, and Drug Product pipelines.

Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners.

ABOUT PACE® LIFE SCIENCES?

Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. More at pacelifesciences.com.

ABOUT PACE®

Pace® makes the world a safer, healthier place. Pace® people are committed to advancing the science of the pharmaceutical and biotechnology industries in our Life sciences laboratories and supporting businesses, industries, consulting firms, government agencies, and more in our Analytical Services Laboratories. Pace® offers local-level service backed by a national laboratory network. For customers with in-house labs, Pace® provides a range of professional services to keep their operations moving forward. Pace® people work in partnership with customers by providing the service, science and data they need to make critical decisions that benefit us all. More at pacelabs.com.

Contact Information

Pam Bednar
Marketing Director
pam.bednar@pacelabs.com
612-297-0651

Brooke Schwartzel
Brand & Communications Manager
brooke.schwartzel@pacelabs.com
612-656-2241

SOURCE: Pace® Life Sciences

.

View the original press release on newswire.com.

© 2024 ACCESSWIRE
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.